

Open Access Article

This Open Access Article is licensed under a <u>Creative Commons Attribution-Non Commercial 3.0 Unported</u> <u>Licence</u> DOI: <u>10.1039/D2RA02896D</u> (Review Article) <u>RSC Adv.</u>, 2022, **12**, 18594-18614

Recent advances in chemistry and therapeutic potential of functionalized quinoline motifs – a review

Olayinka O. Ajani 00*, King T. Iyaye and Olabisi T. Ademosun

Department of Chemistry, Covenant University, Km 10, Idiroko Road, PMB 1023, Ota, Ogun State, Nigeria. E-mail: <u>ola.ajani@covenantuniversity.edu.ng</u>; Tel: +2348061670254

Received 7th May 2022, Accepted 8th June 2022

First published on 24th June 2022

Abstract

Quinoline, which consists of benzene fused with *N*-heterocyclic pyridine, has received considerable attention as a core template in drug design because of its broad spectrum of bioactivity. This review aims to present the recent advances in chemistry, medicinal potential and pharmacological applications of quinoline motifs to unveil their substantial efficacies for future drug development. Essential information in all the current and available literature used was accessed and retrieved using different search engines and databases, including Scopus, ISI Web of Knowledge, Google and PUBMED. Numerous

derivatives of the bioactive quinolines have been harnessed *via* expeditious synthetic approaches, as highlighted herein. This review reveals that quinoline is an indisputable pharmacophore due to its tremendous benefits in medicinal chemistry research and other valuable areas of human endeavour. The recent *in vivo* and *in vitro* screening reported by scientists is highlighted herein, which may pave the way for novel drug development. Owing to the array of information available and highlighted herein on the medicinal potential of quinoline and its functionalized derivatives, a new window of opportunity may be opened to medicinal chemists to access more biomolecular quinolines for future drug development.

1.

This journal is © The Royal Society of Chemistry 2022